IDEAYA Biosciences (IDYA) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	IDYA
Entity Registrant Name	IDEAYA Biosciences, Inc.
Entity Central Index Key	0001676725
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		39,305,802
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-38915
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4268251
Entity Address, Address Line One	7000 Shoreline Court
Entity Address, Address Line Two	Suite 350
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	443-6209
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 49,106	$ 92,046
Short-term marketable securities	219,514	154,724
Accounts receivable	288	1,103
Prepaid expenses and other current assets	3,281	3,123
Total current assets	272,189	250,996
Restricted cash	106	106
Long-term marketable securities	55,171	121,293
Property and equipment, net	7,163	4,763
Right-of-use assets	3,204	3,898
Other non-current assets	174	291
Total assets	338,007	381,347
Current liabilities
Accounts payable	4,227	2,100
Accrued liabilities	16,230	12,320
Contract liability	35,849	29,040
Operating lease liabilities - current	1,783	1,699
Total current liabilities	58,089	45,159
Long-term contract liability	8,025	31,192
Long-term operating lease liabilities	2,572	3,482
Total liabilities	68,686	79,833
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2022 and December 31, 2021; no shares issued and outstanding as of June 30,2022 and December 31, 2021
Common stock, $0.0001 par value, 300,000,000 shares authorized as of June 30, 2022 and December 31, 2022; 38,704,010 and 38,533,045 shares issued and outstanding as of June 30, 2022 and December 31, 2021	4	4
Additional paid-in capital	485,763	478,970
Accumulated other comprehensive loss	(3,629)	(712)
Accumulated deficit	(212,817)	(176,748)
Total stockholders’ equity	269,321	301,514
Total liabilities and stockholders’ equity	$ 338,007	$ 381,347

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	38,704,010	38,533,045
Common stock, shares outstanding	38,704,010	38,533,045

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Collaboration revenue	$ 5,851	$ 8,756	$ 17,210	$ 16,003
Operating expenses
Research and development	22,796	14,979	42,451	26,546
General and administrative	5,554	4,828	11,478	9,643
Total operating expenses	28,350	19,807	53,929	36,189
Loss from operations	(22,499)	(11,051)	(36,719)	(20,186)
Interest income and other income , net	443	104	650	218
Net loss	(22,056)	(10,947)	(36,069)	(19,968)
Unrealized losses on marketable securities	(825)	(3)	(2,917)	(11)
Comprehensive loss	$ (22,881)	$ (10,950)	$ (38,986)	$ (19,979)
Net loss per common share, basic	$ (0.57)	$ (0.33)	$ (0.93)	$ (0.62)
Net loss per common share, diluted	$ (0.57)	$ (0.33)	$ (0.93)	$ (0.62)
Weighted average number of common shares outstanding used in computing net loss per share, basic	38,660,971	32,854,926	38,626,659	32,321,481
Weighted average number of common shares outstanding used in computing net loss per share, diluted	38,660,971	32,854,926	38,626,659	32,321,481

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 198,274	$ 3	$ 325,250	$ 7	$ (126,986)
Beginning balance, shares at Dec. 31, 2020		29,537,216
Issuance of common stock related to at-the-market offering program, net of issuance costs	57,286		57,286
Issuance of common stock related to at-the-market offering program, net of issuance costs, shares		3,407,872
Issuance of common stock upon exercise of stock options	355		355
Issuance of common stock upon exercise of stock options, shares		59,960
Employee stock purchase plan (ESPP) purchase	327		327
Employee stock purchase plan (ESPP) purchase, shares		28,745
Vesting of early exercised common stock options and restricted stock	21		21
Stock-based compensation	3,976		3,976
Other comprehensive loss	(11)			(11)
Net loss	(19,968)				(19,968)
Ending balance at Jun. 30, 2021	240,260	$ 3	387,215	(4)	(146,954)
Ending balance, shares at Jun. 30, 2021		33,033,793
Beginning balance at Mar. 31, 2021	233,125	$ 3	369,130	(1)	(136,007)
Beginning balance, shares at Mar. 31, 2021		32,270,538
Issuance of common stock related to at-the-market offering program, net of issuance costs	15,454		15,454
Issuance of common stock related to at-the-market offering program, net of issuance costs, shares		695,218
Issuance of common stock upon exercise of stock options	243		243
Issuance of common stock upon exercise of stock options, shares		39,292
Employee stock purchase plan (ESPP) purchase	327		327
Employee stock purchase plan (ESPP) purchase, shares		28,745
Vesting of early exercised common stock options and restricted stock	3		3
Stock-based compensation	2,058		2,058
Other comprehensive loss	(3)			(3)
Net loss	(10,947)				(10,947)
Ending balance at Jun. 30, 2021	240,260	$ 3	387,215	(4)	(146,954)
Ending balance, shares at Jun. 30, 2021		33,033,793
Beginning balance at Dec. 31, 2021	301,514	$ 4	478,970	(712)	(176,748)
Beginning balance, shares at Dec. 31, 2021		38,533,045
Issuance of common stock related to at-the-market offering program, net of issuance costs	(75)		(75)
Issuance of common stock related to at-the-market offering program, net of issuance costs, shares		2,173
Issuance of common stock upon exercise of stock options	784		784
Issuance of common stock upon exercise of stock options, shares		122,913
Employee stock purchase plan (ESPP) purchase	435		435
Employee stock purchase plan (ESPP) purchase, shares		45,879
Stock-based compensation	5,649		5,649
Other comprehensive loss	(2,917)			(2,917)
Net loss	(36,069)				(36,069)
Ending balance at Jun. 30, 2022	269,321	$ 4	485,763	(3,629)	(212,817)
Ending balance, shares at Jun. 30, 2022		38,704,010
Beginning balance at Mar. 31, 2022	288,667	$ 4	482,228	(2,804)	(190,761)
Beginning balance, shares at Mar. 31, 2022		38,639,922
Issuance of common stock related to at-the-market offering program, net of issuance costs	(66)		(66)
Issuance of common stock upon exercise of stock options	122		122
Issuance of common stock upon exercise of stock options, shares		18,209
Employee stock purchase plan (ESPP) purchase	435		435
Employee stock purchase plan (ESPP) purchase, shares		45,879
Stock-based compensation	3,044		3,044
Other comprehensive loss	(825)			(825)
Net loss	(22,056)				(22,056)
Ending balance at Jun. 30, 2022	$ 269,321	$ 4	$ 485,763	$ (3,629)	$ (212,817)
Ending balance, shares at Jun. 30, 2022		38,704,010

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (36,069)	$ (19,968)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	974	826
Net amortization (accretion) of premiums (discounts) on marketable securities	518	899
Stock-based compensation	5,649	3,976
Amortization of right-of-use assets	694	642
Changes in assets and liabilities
Accounts receivable	815	552
Prepaid expenses and other assets	(51)	(1,719)
Accounts payable	1,916	796
Accrued and other liabilities	3,099	1,724
Contract liabilities	(16,358)	(13,633)
Lease liabilities	(826)	(749)
Net cash used in operating activities	(39,639)	(26,654)
Cash flows from investing activities
Purchases of property and equipment, net	(2,342)	(1,581)
Purchases of marketable securities	(102,222)	(133,046)
Maturities of marketable securities	100,119	117,663
Sales of marketable securities	0	4,018
Net cash used in investing activities	(4,445)	(12,946)
Cash flows from financing activities
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs	(75)	57,308
Proceeds from ESPP purchase	784	327
Proceeds from exercise of common stock options, net of repurchases	435	355
Net cash provided by financing activities	1,144	57,990
Net increase (decrease) in cash, cash equivalents and restricted cash	(42,940)	18,390
Cash, cash equivalents and restricted cash, at beginning of period	92,152	72,143
Cash, cash equivalents and restricted cash, at end of period	49,212	90,533
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	49,106	90,427
Restricted cash	106	106
Cash, cash equivalents and restricted cash	49,212	90,533
Supplemental disclosure of cash flow information:
Cash paid for income taxes	0	4
Cash paid for interest	32	37
Supplemental non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities	1,021	378
Unpaid offering costs	0	171
Vesting of early exercised options and restricted stock	$ 0	$ 21

Organization

Organization	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of the Business IDEAYA Biosciences, Inc. (the “Company”) is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company is headquartered in South San Francisco, California and was incorporated in the State of Delaware in June 2015. To date, the Company has been primarily engaged in business planning, research, development, recruiting and raising capital. At-the-Market Offering On August 12, 2020, the Company filed a prospectus supplement to the prospectus dated June 10, 2020, activating its at-the-market facility by entering into an open market sale agreement (the “August 2020 Sales Agreement") with Jefferies LLC (“Jefferies”), pursuant to which the Company could offer and sell shares of its common stock with an aggregate offering price of up to $ 50.0 million under an “at the market” offering program. As of January 15, 2021, the Company exhausted all sales under the August 2020 Sales Agreement. On January 20, 2021, the Company entered into a new open market sale agreement (the “January 2021 Sales Agreement”) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $ 90.0 million under an “at the market” offering program. For the six months ended June 30, 2022 , the Company sold an aggregate of 2,173 shares for gross proceeds of $ 0.05 million under the January 2021 Sales Agreement. Liquidity The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $ 212.8 million as of June 30, 2022. The Company has historically financed its operations primarily through the sale of convertible notes, redeemable convertible preferred stock and common stock, and payments received from its collaboration arrangement. To date, none of the Company’s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception. Management expects operating losses to continue and increase for the foreseeable future, as the Company progresses into clinical development activities for its lead product candidates. The Company’s prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry as discussed under Risks and Uncertainties in Note 2. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $ 323.8 million. Management believes that the Company’s current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. Unaudited Condensed Financial Statements The accompanying financial information for the three and six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2022 and its results of operations for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. Accounts receivable represents amounts due from GlaxoSmithKline. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. Summary of Significant Accounting Policies There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K. Revenue Recognition The Company follows Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party’s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the “variable consideration constraint”) that a significant reversal of recognized revenue is not probable. Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. Customer options for additional goods or services: If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company’s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised. Milestone payments: At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. It is not necessary for the Company to use the same approach for all contracts. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of PolQ and WRN program costs which is consistently applied throughout the life of the contract. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company’s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner. Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity’s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis). Upfront payment contract liabilities resulting from the Company’s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Am ounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability. Net Loss per Share Attributable to Common Stockholders Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. New Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The FASB subsequently issued supplemental guidance to ASC 326 within ASU 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief , ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses . ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. ASU 2019-10 extended the effectiveness of Topic 326 for smaller reporting companies until fiscal years beginning after December 15, 2022. ASU 2019-10 requires entities to make a one-time determination of whether an entity is eligible to be a smaller reporting company as of November 15, 2019 for the purpose of determining the effective date of ASU 2016-13. The Company determined that it was eligible to be a smaller reporting company as of November 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of these ASUs will have on its condensed financial statements and related disclosures.

Fair Value Measurement and Mark

Fair Value Measurement and Marketable Securities	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement and Marketable Securities	3. Fair Value Measurement and Marketable Securities The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model . In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. As of June 30, 2022, financial assets measured and recognized at fair value are as follows (in thousands): June 30, 2022 Amortized Gross Gross Estimated Assets U.S. government securities Level 1 $ 140,484 $ — $ ( 2,918 ) $ 137,566 Corporate bonds Level 2 72,275 — ( 710 ) 71,565 Commercial paper Level 2 65,554 — ( 1 ) 65,553 Marketable securities 278,313 — ( 3,629 ) 274,684 Money market funds (1) Level 1 49,195 — — 49,195 Total fair value of assets $ 327,508 $ — $ ( 3,629 ) $ 323,879 (1) Included in cash and cash equivalents on the condensed balance sheets. As of December 31, 2021, financial assets measured and recognized at fair value are as follows (in thousands): December 31, 2021 Amortized Gross Gross Estimated Assets U.S. government securities Level 1 $ 122,657 $ — $ ( 592 ) $ 122,065 Corporate bonds Level 2 76,628 8 ( 127 ) 76,509 Commercial paper Level 2 77,444 — ( 1 ) 77,443 Marketable securities 276,729 8 ( 720 ) 276,017 Money market funds (1) Level 1 91,825 — — 91,825 Total fair value of assets $ 368,554 $ 8 $ ( 720 ) $ 367,842 (1) Included in cash and cash equivalents on the condensed balance sheets. The Company considers available evidence in evaluating potential other-than-temporary impairments of its marketable securities, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. As of June 30, 2022 and December 31, 2021, the Company held certain securities in an unrealized loss position. These unrealized losses were considered to be temporary as the Company expects to recover the entire amortized cost basis on the securities in unrealized loss positions based on the creditworthiness of the underlying issuer, and the Company neither intends to sell these securities nor considers it more likely than not that the Company would be required to sell any such security before its anticipated recovery. As a result, the Company did not consider any of these investments to be other-than-temporarily impaired at June 30, 2022 and December 31, 2021. As of June 30, 2022 and December 31, 2021, all marketable securities had a remaining maturity of less than two years . There were no financial liabilities measured and recognized at fair value as of June 30, 2022 and December 31, 2021 .

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Useful Life June 30, December 31, (In Years) 2022 2021 Laboratory equipment 5 $ 9,298 $ 6,440 Computer equipment 3 262 117 Software 3 242 204 Leasehold improvements Shorter of useful life or lease term 3,301 3,133 Furniture and fixtures 5 506 466 Total property and equipment 13,609 10,360 Less: Accumulated depreciation and amortization ( 6,446 ) ( 5,597 ) Property and equipment, net $ 7,163 $ 4,763 Depreciation and amortization expense was $ 0.5 million and $ 0.4 million for the three months ended June 30, 2022 and June 30, 2021, respectively, and $ 1.0 million and $ 0.8 million for the six months ended June 30, 2022 and June 30, 2021, respectively. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued research and development expenses $ 11,219 $ 7,864 Accrued salaries and benefits 3,475 3,971 Legal and professional fees 726 485 Accrued fixed assets 810 — Accrued liabilities $ 16,230 $ 12,320

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Contingencies From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of June 30, 2022, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company has not recorded a liability related to such indemnification agreements as of June 30, 2022 .

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes For the three and six months ended June 30, 2022 and 2021 , the Company did no t record a federal or state income tax provision due to its recurring net losses. In addition, the Company has taken a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will be realized. Under the Tax Cuts and Jobs Act, for tax years beginning after December 31, 2021, taxpayers are required to capitalize certain research and experimental expenditures and amortize them over five or fifteen years pursuant to the Internal Revenue Code Section 174. Previously, such costs may be deducted in the period they are incurred. As of June 30, 2022 , the Company has performed a high-level assessment of the potential tax impact related to this change in tax law and does not expect to have any material tax impact for the year ending December 31, 2022.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Common Stock	7. Common Stock As of June 30, 2022 and December 31, 2021 , the Company’s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock at a par value of $ 0.0001 per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Company’s board of directors. As of June 30, 2022 and December 31, 2021 , no dividends have been declared to date. The Company had reserved common stock for future issuance as follows: June 30, December 31, 2022 2021 Outstanding options under the 2015 and 2019 Plans 4,922,224 3,620,666 Shares available for grant under the 2019 Plan 1,039,677 922,826 Shares available under the Employee Stock Purchase Plan 942,386 602,935 Total 6,904,287 5,146,427

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation 2019 Incentive Award Plan In May 2019, the Company’s board of directors adopted and the Company’s stockholders approved the 2019 Incentive Award Plan (the “2019 Plan”), under which the Company may grant cash and equity-based incentive awards to the Company’s employees, consultants and directors. Following the effectiveness of the 2019 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the “2015 Plan”). However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that are forfeited or lapse unexercised and which following the effective date of the 2019 Plan are not issued under the 2015 Plan will be available for issuance under the 2019 Plan. Options granted under the 2019 Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The exercise price of an ISO and NSO shall not be less than 100 % of the estimated fair value of the shares on the date of grant. The exercise price of an ISO granted to an employee who, at the time of grant, owns stock representing more than 10 % of the voting power of all classes of stock of the Company (a “10% stockholder”) shall be no less than 110 % of the estimated fair value of the shares on the date of grant. Options granted under the 2019 Plan have a term of 10 years (or five years if granted to a 10% stockholder) and generally vest over a 4 -year period with 1 -year cliff vesting. 2015 Equity Incentive Plan In 2015, the Company established its 2015 Plan which provides for the granting of stock options to employees and consultants of the Company. Options granted under the 2015 Plan may be either ISOs or NSOs. 2019 Employee Stock Purchase Plan In May 2019, the Company’s board of directors adopted and the Company’s stockholders approved the 2019 Employee Stock Purchase Plan (the “ESPP”). The ESPP provides eligible employees with the opportunity to acquire an ownership interest in the Company through periodic payroll deductions up to 15 % of eligible compensation. The offering period is determined by the Company in its discretion but may not exceed 27 months. The per-share purchase price on the applicable exercise date for an offering period is equal to the lesser of 85 % of the fair market value of the common stock at either the first business day or last business day of the offering period, provided that no more than 4,000 shares of common stock may be purchased by any one employee during each offering period. The ESPP is intended to constitute an “employee stock purchase plan” under Section 423(b) of the Internal Revenue Code of 1986, as amended. As of June 30, 2022, a total of 942,386 shares of common stock were reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year. For the six months ended June 30, 2022 and June 30, 2021, the Company recorded $ 0.2 million and $ 0.2 million, respectively, of compensation expense related to participation in the ESPP. Stock-Based Compensation Expense Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 1,603 $ 873 $ 2,901 $ 1,669 General and administrative 1,441 1,185 2,748 2,307 Total stock-based compensation expense $ 3,044 $ 2,058 $ 5,649 $ 3,976 Stock Options Activity under the Company’s 2015 and 2019 Plans is set forth below: Outstanding Options Shares Shares Weighted- Weighted- Aggregate Intrinsic Value (Millions) Balance, January 1, 2022 922,826 3,620,666 $ 12.36 7.92 $ 41.40 Additional shares authorized 1,541,322 — Options granted ( 1,552,180 ) 1,552,180 $ 12.72 Options exercised — ( 122,913 ) $ 6.38 Options canceled 127,709 ( 127,709 ) $ 12.84 Balance, June 30, 2022 1,039,677 4,922,224 $ 12.61 8.26 $ 14.60 Exercisable as of June 30, 2022 1,994,118 $ 9.36 6.99 $ 11.00 Vested and expected to vest as of 4,922,224 $ 12.61 8.26 $ 14.60 The weighted-average grant-date fair value of options granted during the six months ended June 30, 2022 and June 30, 2021 was $ 9.43 and $ 15.71 per share, respectively. The aggregate intrinsic value of options exercised for the six months ended June 30, 2022 and June 30, 2021 was $ 1.0 million and $ 0.9 million, respectively. Intrinsic values are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise. As of June 30, 2022 and December 31, 2021, total unrecognized stock-based compensation expense for stock options was $ 30.1 million and $ 22.2 million, respectively, which is expected to be recognized over a weighted-average period of 2.82 years and 2.61 years, respectively. Early Exercise of Stock Options The terms of the 2015 Plan permit the exercise of options granted under the 2015 Plan prior to vesting, subject to required approvals. The shares so acquired prior to vesting are subject to a lapsing repurchase right in favor of the Company at the original purchase price of such shares, exercisable upon a termination of the holder’s service with the Company prior to full vesting. The proceeds are initially recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. The Company had no repurchases of shares of common stock for the six months ended June 30, 2022 and 2021. There were no shares subject to repurchase as of June 30, 2022 and December 31, 2021. Black-Scholes Assumptions The fair values of options were calculated using the assumptions set forth below: Three Months Ended June 30, Six months Ended June 30, 2022 2021 2022 2021 Expected term 6.1 years 5.5 - 6.1 years 6.1 years 5.5 - 6.1 years Expected volatility 87.5 % - 87.8 % 96.0 % - 102.8 % 87.5 % - 89.9 % 96.0 % - 103.6 % Risk-free interest rate 2.7 % - 3.0 % 0.8 % - 1.1 % 1.6 % - 3.0 % 0.6 % - 1.1 % Dividend yield 0 % 0 % 0 % 0 % Expected term . The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options’ vesting terms, contractual terms and industry peers, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Expected Volatility . As there is insufficient trading history for the Company’s common stock, the Company bases its computation of expected volatility on the historical stock price volatility of its own common stock and that of a representative peer group of public companies with similar characteristics to the Company. For purposes of identifying these peer companies, the Company considers the industry, stage of development, size and financial leverage of potential comparable companies. The historical volatility is calculated based on a period of time commensurate with the expected term assumption for each grant. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Risk-Free Interest Rate . The risk-free rate assumption is based on U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. Expected Dividend Rate . The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero . The Company accounts for forfeitures as they occur. Fair Value of Common Stock The fair value of the Company’s common stock is determined based on its closing market price on the date of grant. Restricted Stock As of June 30, 2022 and December 31, 2021 , there were no shares of restricted stock outstanding. The restricted stock vests upon the achievement of pre-defined research milestones. The holder of restricted stock has voting and dividend rights with respect to such shares held without regard to vesting. Shares of restricted stock are subject to a right of repurchase at the original purchase price held by the Company. The total fair value of restricted stock vested during the six months ended June 30, 2022 and June 30, 2021 was zero and $ 0.1 million, respectively.

Significant Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2022
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements GlaxoSmithKline Collaboration, Option and License Agreement In June 2020, the Company entered into a Collaboration, Option and License Agreement, or the GSK Collaboration Agreement (the "Agreement"), with an affiliate of GlaxoSmithKline, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4), Limited, or GSK, pursuant to which the Company and GSK have entered into a collaboration for its synthetic lethality programs targeting methionine adenosyltransferase 2a, or MAT2A, DNA Polymerase Theta, or Pol Theta or POLQ, and Werner Helicase, or WRN. On July 27, 2020 (the “Effective Date”), the Company and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, or HSR Clearance, and the GSK Collaboration Agreement became effective. Pursuant to the Agreement, GSK paid the Company $ 100.0 million on July 31, 2020. MAT2A Program Under the MAT2A program, the Company is leading research and development efforts through the early clinical development stage. In addition, the Company granted GSK an option to obtain an exclusive license to further the development and commercialization of MAT2A products arising out of the MAT2A program, or the Option. In January 2022, GSK waived its rights under the GSK Collaboration Agreement to initiate, or request that the Company initiate, prior to GSK’s exercise of the Option, a Phase 1 combination clinical trial for a MAT2A product and GSK’s Type I PRMT inhibitor (GSK3368715) product, or the MAT2A Combination Trial. Accordingly, the Company has no further obligation under the GSK Collaboration Agreement to supply MAT2A product for the MAT2A Combination Trial at its own cost. IDEAYA’s obligation to supply the MAT2A compound under MAT2A Combination Study was deemed a material right under the GSK Collaboration Agreement. See Note 10, Revenue Recognition, for more information. The Company delivered an Option data package to GSK pursuant to the GSK Collaboration Agreement comprising preclinical and clinical data resulting from the Company's conduct of a dose-escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Option is exercisable by GSK within a specified period of time. GSK had not informed the Company of its decision on whether to exercise the Option as of June 30, 2022. Subsequent to quarter end, on August 12, 2022, the Company received notice from GSK waiving its rights to exercise its option to obtain an exclusive license to further develop and commercialize IDE397, as well as other IDEAYA compounds, if any, directly targeting MAT2A pursuant to the GSK Collaboration Agreement. As such, the Company has recaptured and fully owns all right, title and interest in and to IDE397 and the MAT2A program, including all worldwide commercial rights thereto. The Company will be responsible for the costs of further research and clinical development activities that the Company conducts for the MAT2A program. Pol Theta Program Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize POLQ products arising out of the POLQ program. GSK and the Company will collaborate on ongoing preclinical research for the POLQ program, and GSK will lead clinical development for the POLQ program. GSK will be responsible for all research and development costs for the POLQ program, including those incurred by the Company. The Company will be eligible to receive future development and regulatory milestones of up to $ 485.0 million, with respect to each POLQ product, including as applicable, for multiple POLQ products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company is eligible to receive up to $ 475.0 million of commercial milestones with respect to each POLQ product. The Company is also entitled to receive tiered royalties on global net sales of POLQ products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. In June 2022, the Company announced the nomination of development candidate selection for the POLQ GLP Toxicology Study Initiation milestone. The milestone remains fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. WRN Program Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. The Company and GSK will collaborate on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with IDEAYA responsible for 20 % and GSK responsible for 80 % of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof. The Company will be eligible to receive future development milestones of up to $ 485.0 million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company will be eligible to receive up to $ 475.0 million of commercial milestones with respect to each WRN product. The Company will be entitled to receive 50 % of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. The Company will have a right to opt-out of the 50 % U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out. General Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, the Company and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN, POLQ, or MAT2A (unless GSK does not exercise the Option, in which case such restriction shall cease to apply with respect to MAT2A) for an agreed upon period of time. The Company and GSK will form a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter. GSK’s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country. Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions. The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either the Company or GSK may terminate the GSK Collaboration Agreement for the other party’s insolvency or certain uncured breaches. The Company may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon 90-day notice to the Company. Pfizer Clinical Trial Collaboration and Supply Agreements In March 2020, the Company entered into a clinical trial collaboration and supply agreement with Pfizer Inc., or the Supply Agreement, as amended in September 2020, April 2021 and August 2021. Pursuant to the Supply Agreement, Pfizer supplies the Company with their MEK inhibitor, binimetinib, and an investigational cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 hotspot mutations. Under the Supply Agreement, the Company will sponsor a Phase 1/2 clinical trial, and Pfizer will supply the Company with binimetinib and crizotinib for use in the clinical trial at no cost to the Company. The Supply Agreement provides that the Company and Pfizer will jointly own clinical data generated from the clinical trial. In March 2022, the Company and Pfizer entered into a second Clinical Trial Collaboration and Supply Agreement, or the Second Pfizer Agreement, pursuant to which the Company may, subject to FDA feedback and guidance, evaluate darovasertib and Pfizer’s investigational cMET inhibitor, crizotinib, as a combination therapy in MUM in a planned Phase 2 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, the Company is the sponsor of the planned combination trial and will provide darovasertib and pay for the costs of the combination trial; Pfizer will provide crizotinib for the planned combination trial at no cost to the Company. The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of IDE196 and crizotnib. The Company and Pfizer will form a joint development committee responsible for coordinating all regulatory and other activities under the Second Pfizer Agreement. Separately, in March 2022, the Company and Pfizer also entered into a third Clinical Trial Collaboration and Supply Agreement, or the Third Pfizer Agreement, pursuant to which the Company may, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and Pfizer’s investigational cMET inhibitor, crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, the Company is the sponsor of the planned combination trial and will provide darovasertib and pay for the costs of the combination trial; Pfizer will provide crizotinib for the planned combination trial at no cost to the Company. The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotnib. The Company and Pfizer will form a joint development committee responsible for coordinating all regulatory and other activities under the Third Pfizer Agreement. Novartis License Agreement In September 2018, the Company entered into a license agreement with Novartis International Pharmaceuticals Ltd. (“Novartis”) to develop and commercialize Novartis’ LXS196 (also known as IDE196), a Phase 1 protein kinase C (“PKC”) inhibitor for the treatment of cancers having GNAQ and GNA11 mutations. Under the license agreement, the Company is liable to make contingent development and sales-based milestone payments of up to $ 29.0 million and mid to high single-digit royalty payments based on net sales of the licensed products. Because the achievement of these milestones had not occurred or was not considered probable as of June 30, 2022, such contingencies have not been recorded in the Company's condensed consolidated financial statements. Cancer Research Technology Ltd. and the University of Manchester License Agreement In January 2022, the Company exercised its option for an exclusive worldwide license covering a broad class of PARG inhibitors from Cancer Research Technology Ltd. (CRT) and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of £ 250,000 . The Company will be obligated to make payments to CRT aggregating up to £ 19.5 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. The Company will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event the Company sublicenses the intellectual property, it will also be obligated to pay CRT a specified percentage of any sublicense revenue.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	10. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 for the GSK Collaboration Agreement (see Note 9, Significant Agreements). Disaggregation of Revenue The following table presents revenue disaggregated by research program (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 MAT2A $ 3,740 $ 1,763 $ 11,599 $ 3,230 Pol Theta 1,224 5,074 3,344 8,609 WRN 887 1,919 2,267 4,164 Total collaboration revenue $ 5,851 $ 8,756 $ 17,210 $ 16,003 Contract balances The following table presents the significant changes in the balance of contract liabilities during the six months ended June 30, 2022 (in thousands): Contract liabilities Balance as of December 31, 2021 $ 60,232 Reclassification to revenue, as the result of performance obligations satisfied ( 17,210 ) Cash received for cost reimbursements 564 Increase in accounts receivable 288 Balance as of June 30, 2022 $ 43,874 The timing of revenue recognition, billings, and cash collections results in accounts receivable, contract assets, and contract liabilities on the balance sheets. Based on the estimated reimbursable program costs for a quarter, the Company recognizes accounts receivable, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are derecognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Performance obligations The Company has identified the following six performance obligations associated with the GSK Collaboration Agreement: (i) Preclinical and Phase 1 Monotherapy clinical research and development services under the MAT2A program (“MAT2A R&D Services”) (ii) Preclinical research services and the related license to IDEAYA-owned technology under the Pol Theta program (“Pol Theta R&D Services”) (iii) Preclinical research services and the related license to IDEAYA-owned technology under the WRN program (“WRN R&D Services”) (iv) Material right associated with the option to license IDEAYA-owned technology under the MAT2A program (defined as the “Option” in Note 9) (v) Material right associated with the option to license to IDEAYA-owned technology under the MAT2A program to the extent necessary for preclinical activities in preparation for the MAT2A Combination Trial (“Preclinical MAT2A License”) (vi) Material right associated with the supply of MAT2A product for the MAT2A Combination Trial (“MAT2A Supply”) The Company will recognize revenue related to amounts allocated to the MAT2A R&D services as the underlying services are performed over the period through the delivery of the Option data package, which will be generated from its conduct of the dose escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Company uses its internal research and development capability and may also engage third-party clinical research organizations, or CROs, in transferring the MAT2A R&D services, for which the Company acts as a principal. The Company has delivered the Option data package to GSK. Accordingly, the performance obligation related to the MAT2A R&D services has been fulfilled. With respect to the Pol Theta and WRN programs, the Company identified two promises: (1) granting of the license to develop and commercialize Pol Theta and WRN products, respectively, and (2) the preclinical research services. The Company has determined that these two promises are not distinct within the context of the contract. As of the Effective Date of the GSK Collaboration Agreement, both programs were at an early stage, and the Company was yet to identify any development candidate for either program, which will require the completion of certain preclinical studies. After the Company and GSK identify a development candidate, a series of IND-enabling studies will be conducted before an Investigational New Drug application is submitted to the FDA. Due to the early stage of development, the Company’s preclinical research services are expected to transform the underlying technology and significantly modify or customize the license. Therefore, the two promises are not distinct from each other and are accounted for as a single performance obligation for each of the Pol Theta and WRN programs, respectively. The Company will recognize revenue related to amounts allocated to the Pol Theta R&D Services and WRN R&D Services as the underlying services are performed over the period through the completion of the Pol Theta and WRN preclinical research programs, respectively. Within 90 days from the end of each calendar quarter, GSK will reimburse the Pol Theta program costs incurred by the Company. Within 75 days from the end of each calendar quarter, the Company and GSK will determine the amounts of WRN program costs incurred by both parties and the net amount owed by GSK to the Company or by the Company to GSK, which will be paid within 75 days from such determination by a reimbursing party. The Company uses its internal research capability and may also engage third-party clinical research organizations, or CROs, in transferring the Pol Theta R&D services and WRN R&D services, for which the Company acts as a principal. Upon exercise of the Option, at Option closing following HSR clearance, GSK will obtain an exclusive license to develop and commercialize MAT2A products. The Company has concluded that this Option results in a material right as the option exercise fee contains a discount that GSK would not have otherwise received. The Company has determined the nature of the license to develop and commercialize MAT2A products to be functional. After exercise of the Option, and subject to HSR clearance and Option closing, the Company will recognize revenue, when it makes the underlying MAT2A technology available to GSK, which will immediately be able to use and benefit from its right to use the intellectual property. The Company has identified two additional customer options under the MAT2A program, both of which have been determined a material right. GSK may elect to conduct certain preclinical activities in preparation for the MAT2A Combination Trial and may elect to exercise the option to license to MAT2A technology. GSK may be able to use and exploit the license to the extent necessary for GSK’s performance of such preclinical activities. The Company will not receive any consideration for providing such license and has concluded that this license option results in a material right as it involves a discount that GSK would not have otherwise received. The Company has determined the nature of such license to MAT2A technology to be functional. During the year ended December 31, 2020, GSK exercised the Preclinical MAT2A License, and the Company has made the underlying MAT2A technology available to GSK, which is immediately able to use and benefit from its right to use the intellectual property. Accordingly, the Company recognized revenue from the Preclinical MAT2A License in the year ended December 31, 2020. If GSK elects to conduct the MAT2A Combination Trial, the Company will supply MAT2A product to be used for the MAT2A Combination Trial at its own cost. The Company has concluded that this supply option results in a material right as it involves a discount that GSK would not have otherwise received. The Company will recognize revenue, as it transfers the control of the MAT2A product to GSK. In January 2022, GSK waived its rights under the GSK Collaboration Agreement to conduct the MAT2A Combination Trial. Accordingly, the Company recognized revenue of $ 2.4 million related to the material right to supply MAT2A compound as the material right no longer exists and the Company has no further obligation related to the MAT2A Combination Trial. Transaction price allocated to the remaining performance obligations The following table presents the transaction price allocated to the remaining performance obligations as of June 30, 2022 (in thousands): Performance Obligations Allocation of Transaction Price Pol Theta R&D Services $ 9,998 WRN R&D Services 18,155 MAT2A Option 17,470 Total transaction price allocated to the remaining performance obligations $ 45,623 The Company applies the sales-based royalty exception to the commercial milestones and tiered royalties for all programs because GSK would ascribe significantly more value to the license than to the other goods or services to which the commercial milestones and tiered royalties relate. The Company will be entitled to receive the commercial milestones either when the first commercial sale occurs, or when the predefined net sales in a calendar year are achieved, upon which the variability will be resolved. Also, the Company will be entitled to receive the tiered royalties during a calendar year when global net sales of each product occur, upon which the variability will be resolved.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	11. Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Six Months Ended 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ ( 22,056 ) $ ( 10,947 ) $ ( 36,069 ) $ ( 19,968 ) Denominator: Weighted-average shares outstanding 38,660,971 32,864,249 38,626,659 32,334,859 Less: weighted-average unvested restricted shares and — ( 9,323 ) — ( 13,378 ) Weighted-average shares used in computing net loss 38,660,971 32,854,926 38,626,659 32,321,481 Net loss per share attributable to common stockholders, $ ( 0.57 ) $ ( 0.33 ) $ ( 0.93 ) $ ( 0.62 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of June 30, 2022 2021 Options to purchase common stock 4,922,224 3,645,582 Unvested restricted stock awards — 7,313 Unvested early exercised common stock options — 1,255 Total 4,922,224 3,654,150

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events From July 1, 2022 through August 12, 2022, the Company sold an aggregate of 599,671 shares of its common stock for aggregate net proceeds of $ 9.0 million at a weighted average sales price of approximately $ 15.53 per share under the at-the-market offering pursuant to the January 2021 Sales Agreement with Jefferies as sales agent. In July 2022, the Company entered into a Clinical Trial Collaboration and Supply Agreement, or Amgen CTCSA, with Amgen Inc., or Amgen, to clinically evaluate IDE397, the Company's investigational MAT2A inhibitor, in combination with AMG 193, Amgen’s investigational small molecule MTA-cooperative inhibitor of PRMT5, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial. Under the mutually non-exclusive Amgen CTCSA, the Company will provide IDE397 drug supply to Amgen, who will be the sponsor of the Phase 1 clinical combination trial evaluating IDE397 and AMG 193. The Company and Amgen will jointly share external costs of the study and will jointly oversee clinical development of the combination therapy through a Joint Oversight Committee responsible for coordinating all regulatory and other activities under the Amgen CTCSA. The parties will jointly own collaboration data and combination-related intellectual property, if any, arising from the combination clinical trial. The Company and Amgen each retain commercial rights to their respective compounds, including with respect to use as a monotherapy agent or as combination agent. On August 12, 2022, the Company received notice from GSK waiving its rights to exercise its option to obtain an exclusive license to further develop and commercialize IDE397, as well as other IDEAYA compounds, if any, directly targeting MAT2A pursuant to the GSK Collaboration Agreement. As such, the Company has recaptured and fully owns all right, title and interest in and to IDE397 and the MAT2A program, including all worldwide commercial rights thereto.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC.
Unaudited Condensed Financial Statements	Unaudited Condensed Financial Statements The accompanying financial information for the three and six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2022 and its results of operations for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. Accounts receivable represents amounts due from GlaxoSmithKline. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection.
Revenue Recognition	Revenue Recognition The Company follows Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party’s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the “variable consideration constraint”) that a significant reversal of recognized revenue is not probable. Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. Customer options for additional goods or services: If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company’s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised. Milestone payments: At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. It is not necessary for the Company to use the same approach for all contracts. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of PolQ and WRN program costs which is consistently applied throughout the life of the contract. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company’s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner. Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity’s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis). Upfront payment contract liabilities resulting from the Company’s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Am ounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. New Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The FASB subsequently issued supplemental guidance to ASC 326 within ASU 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief , ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses . ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. ASU 2019-10 extended the effectiveness of Topic 326 for smaller reporting companies until fiscal years beginning after December 15, 2022. ASU 2019-10 requires entities to make a one-time determination of whether an entity is eligible to be a smaller reporting company as of November 15, 2019 for the purpose of determining the effective date of ASU 2016-13. The Company determined that it was eligible to be a smaller reporting company as of November 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of these ASUs will have on its condensed financial statements and related disclosures.
Fair Value Measurement and Marketable Securities	The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model .
Early Exercise of Stock Options	Early Exercise of Stock Options The terms of the 2015 Plan permit the exercise of options granted under the 2015 Plan prior to vesting, subject to required approvals. The shares so acquired prior to vesting are subject to a lapsing repurchase right in favor of the Company at the original purchase price of such shares, exercisable upon a termination of the holder’s service with the Company prior to full vesting. The proceeds are initially recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses.
Share Based Compensation Forfeiture	The Company accounts for forfeitures as they occur.

Fair Value Measurement and Ma_2

Fair Value Measurement and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured and Recognized at Fair Value	As of June 30, 2022, financial assets measured and recognized at fair value are as follows (in thousands): June 30, 2022 Amortized Gross Gross Estimated Assets U.S. government securities Level 1 $ 140,484 $ — $ ( 2,918 ) $ 137,566 Corporate bonds Level 2 72,275 — ( 710 ) 71,565 Commercial paper Level 2 65,554 — ( 1 ) 65,553 Marketable securities 278,313 — ( 3,629 ) 274,684 Money market funds (1) Level 1 49,195 — — 49,195 Total fair value of assets $ 327,508 $ — $ ( 3,629 ) $ 323,879 (1) Included in cash and cash equivalents on the condensed balance sheets. As of December 31, 2021, financial assets measured and recognized at fair value are as follows (in thousands): December 31, 2021 Amortized Gross Gross Estimated Assets U.S. government securities Level 1 $ 122,657 $ — $ ( 592 ) $ 122,065 Corporate bonds Level 2 76,628 8 ( 127 ) 76,509 Commercial paper Level 2 77,444 — ( 1 ) 77,443 Marketable securities 276,729 8 ( 720 ) 276,017 Money market funds (1) Level 1 91,825 — — 91,825 Total fair value of assets $ 368,554 $ 8 $ ( 720 ) $ 367,842 (1) Included in cash and cash equivalents on the condensed balance sheets.

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): Useful Life June 30, December 31, (In Years) 2022 2021 Laboratory equipment 5 $ 9,298 $ 6,440 Computer equipment 3 262 117 Software 3 242 204 Leasehold improvements Shorter of useful life or lease term 3,301 3,133 Furniture and fixtures 5 506 466 Total property and equipment 13,609 10,360 Less: Accumulated depreciation and amortization ( 6,446 ) ( 5,597 ) Property and equipment, net $ 7,163 $ 4,763
Summary of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued research and development expenses $ 11,219 $ 7,864 Accrued salaries and benefits 3,475 3,971 Legal and professional fees 726 485 Accrued fixed assets 810 — Accrued liabilities $ 16,230 $ 12,320

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of Number of Common Stock Reserved for Future Issuance	The Company had reserved common stock for future issuance as follows: June 30, December 31, 2022 2021 Outstanding options under the 2015 and 2019 Plans 4,922,224 3,620,666 Shares available for grant under the 2019 Plan 1,039,677 922,826 Shares available under the Employee Stock Purchase Plan 942,386 602,935 Total 6,904,287 5,146,427

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 1,603 $ 873 $ 2,901 $ 1,669 General and administrative 1,441 1,185 2,748 2,307 Total stock-based compensation expense $ 3,044 $ 2,058 $ 5,649 $ 3,976
Summary of Activity under Plans	Activity under the Company’s 2015 and 2019 Plans is set forth below: Outstanding Options Shares Shares Weighted- Weighted- Aggregate Intrinsic Value (Millions) Balance, January 1, 2022 922,826 3,620,666 $ 12.36 7.92 $ 41.40 Additional shares authorized 1,541,322 — Options granted ( 1,552,180 ) 1,552,180 $ 12.72 Options exercised — ( 122,913 ) $ 6.38 Options canceled 127,709 ( 127,709 ) $ 12.84 Balance, June 30, 2022 1,039,677 4,922,224 $ 12.61 8.26 $ 14.60 Exercisable as of June 30, 2022 1,994,118 $ 9.36 6.99 $ 11.00 Vested and expected to vest as of 4,922,224 $ 12.61 8.26 $ 14.60
Assumptions Used to Calculate Fair Values of Options	The fair values of options were calculated using the assumptions set forth below: Three Months Ended June 30, Six months Ended June 30, 2022 2021 2022 2021 Expected term 6.1 years 5.5 - 6.1 years 6.1 years 5.5 - 6.1 years Expected volatility 87.5 % - 87.8 % 96.0 % - 102.8 % 87.5 % - 89.9 % 96.0 % - 103.6 % Risk-free interest rate 2.7 % - 3.0 % 0.8 % - 1.1 % 1.6 % - 3.0 % 0.6 % - 1.1 % Dividend yield 0 % 0 % 0 % 0 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Revenue Disaggregated by Research Program	The following table presents revenue disaggregated by research program (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 MAT2A $ 3,740 $ 1,763 $ 11,599 $ 3,230 Pol Theta 1,224 5,074 3,344 8,609 WRN 887 1,919 2,267 4,164 Total collaboration revenue $ 5,851 $ 8,756 $ 17,210 $ 16,003
Summary of Contract Balances	The following table presents the significant changes in the balance of contract liabilities during the six months ended June 30, 2022 (in thousands): Contract liabilities Balance as of December 31, 2021 $ 60,232 Reclassification to revenue, as the result of performance obligations satisfied ( 17,210 ) Cash received for cost reimbursements 564 Increase in accounts receivable 288 Balance as of June 30, 2022 $ 43,874
Summary of Transaction Price Allocated to Remaining Performance Obligations	The following table presents the transaction price allocated to the remaining performance obligations as of June 30, 2022 (in thousands): Performance Obligations Allocation of Transaction Price Pol Theta R&D Services $ 9,998 WRN R&D Services 18,155 MAT2A Option 17,470 Total transaction price allocated to the remaining performance obligations $ 45,623

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Six Months Ended 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ ( 22,056 ) $ ( 10,947 ) $ ( 36,069 ) $ ( 19,968 ) Denominator: Weighted-average shares outstanding 38,660,971 32,864,249 38,626,659 32,334,859 Less: weighted-average unvested restricted shares and — ( 9,323 ) — ( 13,378 ) Weighted-average shares used in computing net loss 38,660,971 32,854,926 38,626,659 32,321,481 Net loss per share attributable to common stockholders, $ ( 0.57 ) $ ( 0.33 ) $ ( 0.93 ) $ ( 0.62 )
Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of June 30, 2022 2021 Options to purchase common stock 4,922,224 3,645,582 Unvested restricted stock awards — 7,313 Unvested early exercised common stock options — 1,255 Total 4,922,224 3,654,150

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($)			3 Months Ended	6 Months Ended
	Jan. 20, 2021	Aug. 12, 2020	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Subsidiary Sale Of Stock [Line Items]
Accumulated deficit				$ 212,817,000		$ 176,748,000
Cash, cash equivalents and marketable securities				$ 323,800,000
Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares			695,218	2,173	3,407,872
At The Market Offering | Jefferies LLC | August 2020 Sales Agreement | Common Stock | Maximum
Subsidiary Sale Of Stock [Line Items]
Sale of common stock aggregate offering price		$ 50,000,000
At The Market Offering | Jefferies LLC | January 2021 Sales Agreement | Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares				2,173
Gross proceeds from issuance of common stock upon public offering				$ 50,000
At The Market Offering | Jefferies LLC | January 2021 Sales Agreement | Common Stock | Maximum
Subsidiary Sale Of Stock [Line Items]
Sale of common stock aggregate offering price	$ 90,000,000

Fair Value Measurement and Ma_3

Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	$ 278,313	$ 276,729
Marketable securities, gross unrealized gains	0	8
Marketable securities, gross unrealized losses	(3,629)	(720)
Marketable securities, estimated fair value	274,684	276,017
Amortized Cost	327,508	368,554
Estimated Fair Value	323,879	367,842
U.S. Government Securities | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	140,484	122,657
Marketable securities, gross unrealized gains	0	0
Marketable securities, gross unrealized losses	(2,918)	(592)
Marketable securities, estimated fair value	137,566	122,065
Corporate Bonds | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	72,275	76,628
Marketable securities, gross unrealized gains	0	8
Marketable securities, gross unrealized losses	(710)	(127)
Marketable securities, estimated fair value	71,565	76,509
Commercial Paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	65,554	77,444
Marketable securities, gross unrealized gains	0	0
Marketable securities, gross unrealized losses	(1)	(1)
Marketable securities, estimated fair value	65,553	77,443
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Money market funds, amortized Cost	49,195	91,825
Money market funds, estimated Fair Value	$ 49,195	$ 91,825

Fair Value Measurement and Ma_4

Fair Value Measurement and Marketable Securities - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial liabilities recognized at fair value	$ 0	$ 0
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities remaining maturity period	2 years	2 years

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment	$ 13,609	$ 10,360
Less: Accumulated depreciation and amortization	(6,446)	(5,597)
Property and equipment, net	7,163	4,763
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 9,298	6,440
Property and equipment net, useful life	5 years
Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 262	117
Property and equipment net, useful life	3 years
Software
Property Plant And Equipment [Line Items]
Total property and equipment	$ 242	204
Property and equipment net, useful life	3 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 3,301	3,133
Property and equipment net, useful life	Shorter of useful life or lease term
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	$ 506	$ 466
Property and equipment net, useful life	5 years

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Depreciation and amortization expense	$ 0.5	$ 0.4	$ 1	$ 0.8

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Accrued research and development expenses	$ 11,219	$ 7,864
Accrued salaries and benefits	3,475	3,971
Legal and professional fees	726	485
Accrued fixed assets	810	0
Accrued liabilities	$ 16,230	$ 12,320

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Examination [Line Items]
Federal or state income tax provision	$ 0	$ 0	$ 0	$ 0
Maximum
Income Tax Examination [Line Items]
Research and experimental expenditures amortize period (in years)			15 years
Minimum
Income Tax Examination [Line Items]
Research and experimental expenditures amortize period (in years)			5 years

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) Vote $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized | shares	300,000,000	300,000,000
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Common stock, voting rights	Each share of common stock is entitled to one vote.
Number of common stock voting rights held per share | Vote	1
Common stock, dividends declared | $	$ 0	$ 0

Common Stock - Schedule of Numb

Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	6,904,287	5,146,427
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	942,386	602,935
Outstanding Options | 2015 and 2019 Plans
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	4,922,224	3,620,666
Shares available for grant | 2019 Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	1,039,677	922,826

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance	6,904,287		6,904,287		5,146,427
Stock-based compensation expense	$ 3,044,000	$ 2,058,000	$ 5,649,000	$ 3,976,000
Weighted-average grant-date fair value of options granted			$ 9.43	$ 15.71
Aggregate intrinsic value of options exercised			$ 1,000,000	$ 900,000
Total unrecognized stock-based compensation expense for stock options	$ 30,100,000		$ 30,100,000		$ 22,200,000
Total unrecognized stock-based compensation expense, weighted-average period of recognition			2 years 9 months 25 days		2 years 7 months 9 days
Common stock repurchased			0	0
Estimated dividend yield	0%	0%	0%	0%
Unvested Early Exercised Common Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares subject to repurchase	0		0		0
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of stock vested			$ 0	$ 100,000
Shares of restricted stock	0		0		0
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of options			10 years
Vesting period of options			4 years
2019 Equity Incentive Plan | Cliff Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options			1 year
2019 Equity Incentive Plan | 10% Stockholder
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of options			5 years
2019 Equity Incentive Plan | Incentive Stock Options and Nonqualified Stock Options | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fair value of the shares on the grant date			100%
2019 Equity Incentive Plan | Incentive Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of voting power of all classes of stock			10%
2019 Equity Incentive Plan | Incentive Stock Options | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fair value of the shares on the grant date			110%
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance	942,386		942,386
Stock-based compensation expense			$ 200,000	$ 200,000
Maximum offering period under ESPP			27 months
Maximum eligible rate of compensation	15%		15%
2019 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of the fair value of common stock	85%		85%
Maximum number of shares purchasable	4,000		4,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,044	$ 2,058	$ 5,649	$ 3,976
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,603	873	2,901	1,669
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,441	$ 1,185	$ 2,748	$ 2,307

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Activity under Plans (Details) - 2015 and 2019 Plans $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Options, Shares available for Grant, Beginning balance	922,826
Outstanding Options, Shares available for Grant, Additional shares authorized	1,541,322
Outstanding Options, Shares available for Grant, Options granted	(1,552,180)
Outstanding Options, Shares available for Grant, Options exercised	0
Outstanding Options, Shares available for Grant, Options canceled	127,709
Outstanding Options, Shares available for Grant, Ending balance	1,039,677	922,826
Outstanding Options, Shares, Beginning balance	3,620,666
Outstanding Options, Shares, Options granted	1,552,180
Outstanding Options, Shares, Options exercised	(122,913)
Outstanding Options, Shares, Options canceled	(127,709)
Outstanding Options, Shares, Ending balance	4,922,224	3,620,666
Outstanding Options, Shares, Exercisable	1,994,118
Outstanding Options, Shares, Vested and expected to vest	4,922,224
Outstanding Options, Weighted-Average Exercise Price, Beginning balance | $ / shares	$ 12.36
Outstanding Options, Weighted-Average Exercise Price, Options granted | $ / shares	12.72
Outstanding Options, Weighted-Average Exercise Price, Options exercised | $ / shares	6.38
Outstanding Options, Weighted-Average Exercise Price, Options canceled | $ / shares	12.84
Outstanding Options, Weighted-Average Exercise Price, Ending balance | $ / shares	12.61	$ 12.36
Outstanding Options, Weighted-Average Exercise Price, Exercisable | $ / shares	9.36
Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest | $ / shares	$ 12.61
Outstanding Options, Weighted Average Remaining Contractual Term (Years)	8 years 3 months 3 days	7 years 11 months 1 day
Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 11 months 26 days
Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	8 years 3 months 3 days
Outstanding Options, Aggregate Intrinsic Value | $	$ 14,600	$ 41,400
Outstanding Options, Aggregate Intrinsic Value, Exercisable | $	11,000
Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest | $	$ 14,600

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 1 month 6 days		6 years 1 month 6 days
Expected volatility, minimum	87.50%	96%	87.50%	96%
Expected volatility, maximum	87.80%	102.80%	89.90%	103.60%
Risk-free interest rate, minimum	2.70%	0.80%	1.60%	0.60%
Risk-free interest rate, maximum	3%	1.10%	3%	1.10%
Dividend yield	0%	0%	0%	0%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term		5 years 6 months		5 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term		6 years 1 month 6 days		6 years 1 month 6 days

Significant Agreements - Additi

Significant Agreements - Additional Information (Details)		1 Months Ended
	Jul. 31, 2020 USD ($)	Jan. 31, 2022 GBP (£)	Jun. 30, 2020 USD ($)	Sep. 30, 2018 USD ($)
License Agreement | Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time option exercise fee | £		£ 250,000
Payments for achievement of specific development and regulatory approval events | £		£ 19,500,000
Maximum | License Agreement | Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development and sales-based milestone payments				$ 29,000,000
GSK Collaboration Agreement | GSK | License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 100,000,000
Number of days of notice period for terminating agreement			90 days
Pol Theta Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive			$ 485,000,000
Commercial milestone payment eligible to receive			$ 475,000,000
WRN Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage			20%
Percentage of profit share			50%
WRN Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payment eligible to receive			$ 475,000,000
Development milestone payment eligible to receive			$ 485,000,000
WRN Program | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage			80%

Revenue Recognition - Summary o

Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	$ 5,851	$ 8,756	$ 17,210	$ 16,003
MAT2A Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	3,740	1,763	11,599	3,230
Pol Theta Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	1,224	5,074	3,344	8,609
WRN Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	$ 887	$ 1,919	$ 2,267	$ 4,164

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Changes in Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Balance as of December 31, 2021	$ 60,232
Reclassification to revenue, as the result of performance obligations satisfied	(17,210)
Cash received for cost reimbursements	564
Increase in accounts receivable	288
Balance as of June 30, 2022	$ 43,874

Revenue Recognition - Performan

Revenue Recognition - Performance Obligations - Additional Information (Details) $ in Millions			6 Months Ended
	Jan. 31, 2022 USD ($)	Jul. 27, 2020 Obligation	Jun. 30, 2022 Option
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
Number of additional customer options under the MAT2A program | Option			2
MAT2A Supply
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue recognized | $	$ 2.4
GSK
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
GSK Collaboration Agreement
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Number of performance obligations | Obligation		6
Pol Theta Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			90 days
WRN Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
Determination period of costs incurred			75 days

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Transaction Price Allocated to Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 45,623
Pol Theta R&D Services
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	9,998
WRN R&D Services
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	18,155
MAT2A Option
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 17,470

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (22,056)	$ (10,947)	$ (36,069)	$ (19,968)
Denominator:
Weighted-average shares outstanding	38,660,971	32,864,249	38,626,659	32,334,859
Less: weighted-average unvested restricted shares and shares subject to repurchase		(9,323)		(13,378)
Weighted average number of common shares outstanding used in computing net loss per share, basic	38,660,971	32,854,926	38,626,659	32,321,481
Weighted average number of common shares outstanding used in computing net loss per share, diluted	38,660,971	32,854,926	38,626,659	32,321,481
Net loss per common share, basic	$ (0.57)	$ (0.33)	$ (0.93)	$ (0.62)
Net loss per common share, diluted	$ (0.57)	$ (0.33)	$ (0.93)	$ (0.62)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities	4,922,224	3,654,150
Options to purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities	4,922,224	3,645,582
Unvested Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities		7,313
Unvested Early Exercised Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities		1,255

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Common Stock - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Aug. 12, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares		695,218	2,173	3,407,872
At The Market Offering | Jefferies LLC | January 2021 Sales Agreement
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares			2,173
Proceeds from issuance of common stock upon public offering, net of issuance costs			$ 50
Subsequent Event | At The Market Offering | Jefferies LLC | January 2021 Sales Agreement
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares	599,671
Proceeds from issuance of common stock upon public offering, net of issuance costs	$ 9,000
Weighted average sales price per share	$ 15.53